CXCR4 and breast carcinoma: If changes in c-erbB2 and CXCR4 expressions are confirmed as being associated with clinical survival in patients in operable breast cancer, then these may be useful objective response markers to evaluate the clinical response of neo-adjuvant chemotherapy and select the appropriate chemotherapy regimen for postoperative chemotherapy.